Our experience sets us apart . . .
Trials
Drug Class | Indication | Phase | Subjects | Sites |
ACE Inhibitor +Cardioprotective Agent | Hypertension and Type 2 Diabetes | Phase 2 | 160 | 12 |
Antibiotic | Skin Infections and Bacteremia in Renal Impairment | Phase 4 | 92 | 10 |
Anti-thrombotic | CAD | 10 | ||
Cardio and Renal Protective Agent | Percutaneous Coronary Intervention/Acute Kidney Injury | Phase 2 | 361 | 30 |
Cardioprotective Agent | CABG | Phase 3 | 3025 | 139 |
Cardioprotective Agent | CABG | Phase 2/3 | 902 | 42 |
Cardioprotective Agent | Cognitive Deficits | Phase 2 | 400 | 41 |
Cardioprotective Agent | PCI | Phase 2 | 60 | 4 |
Cardioprotective agent | Percutaneous Coronary Intervention | Phase 2a | 120 | 6 |
Cholesterol lowering agent | High Risk Acute Coronary Syndrome | Phase 3 | 80 | 8 |
GPIIb/IIIa Inhibitor | Percutaneous Coronary Intervention | Phase 2 | 675 | 13 |
Heptagonist (Heparin Reversal Agent) | Percutaneous Coronary Intervention | Phase 2 | 17 | 10 |
Hormone | Male Contraceptive | Phase 2 | 321 | 10 |
Insulin Sensitizer | Type 2 Diabetes | Phase 2 | 40 | 3 |
Insulin Sensitizer | Type 2 Diabetes | Phase 2 | 20 | 1 |
Insulin Sensitizer | Type 2 Diabetes | Phase 2 | 64 | 12 |
Kallikrein inhibitor | CABG | Phase 2 | 300 | 38 |
Kallikrein inhibitor | CABG | Phase 2 | 344 | 35 |
Nitroxyl (HNO) Donor | Congestive Heart Failure | Phase 1/2 | 36 | 6 |
Stent (Device Trial) | Abdominal Aortic Aneurysm | Phase 2 | 275 | 45 |
Thrombin receptor antagonist | Non-ST –segment Elevation Acute Coronary Syndrome | Phase 3 | 100 | 10 |
MC-1 | Tardive Dyskinesia | Phase 2 | 53 | 5 |